Caesarea, Israel-based Icecure Medical Ltd. has won the FDA’s nod for additional indications for its cryoablation technology, paving the way for use in kidney, liver, ear, nose and throat and new neurology indications. The agency also cleared Icecure’s new Multisense system.
A mitochondrial glutamine transporter variant of the SLC1A5 gene is a key regulator of glutamine metabolism and metabolic reprogramming in cancer cells, and targeting such transporters could be a new strategy for controlling tumor growth, Korean researchers reported online in the Dec. 19, 2019, edition of Cell Metabolism.
BEIJING – Yisheng Biopharma Co. Ltd., of Beijing, said it has inked a pact with U.S. biotech Tavotek Biotherapeutics, of Ambler, Pa., to co-develop a combination therapy with Yisheng’s YS-ON-001/002 and Tavotek’s Tavo-301/303, which the companies hope could prove a more efficacious cancer treatment than the popular anti-PD-1/PD-L1 monotherapies.
RSS
